Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross- serovar protection against intranasal challenge with chlamydia trachomatis

Infection and Immunity

Volumn 81, Issue 5, 2013, Pages 1741-1750

  Tifrea, Delia F ^a   Ralli Jain, Pooja ^a   Pal, Sukumar ^a   De la Maza, Luis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 4; OUTER MEMBRANE PROTEIN; RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CROSS REACTION; FOLLOW UP; HUMORAL IMMUNITY; IMMUNIZATION; LIMIT OF DETECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; T LYMPHOCYTE; VACCINATION; WEIGHT CHANGE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BODY WEIGHT; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; CHLAMYDIA TRACHOMATIS; COLONY COUNT, MICROBIAL; FEMALE; IMMUNITY, HUMORAL; LUNG; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINATION;

EID: 84877794835     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00734-12     Document Type: Article

References (70)

1. Schachter J, Dawson C. 1978. Human chlamydial infections. PSG Publishing Co., Littleton, CO.
2. CDC. 2009. Chlamydia screening among sexually active young female enrollees of health plans-United States, 2000 -2007. MMWR Morb. Mortal. Wkly. Rep. 58:362-365.
3. Ness RB, Smith KJ, Chang CC, Schisterman EF, Bass DC. 2006. Prediction of pelvic inflammatory disease among young, single, sexually active women. Sex. Transm. Dis. 33:137-142.
4. Darville T. 2006. Chlamydia trachomatis genital infection in adolescents and young adults. Adv. Exp. Med. Biol. 582:85-100.
5. Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM, Cohen MS, Harris KM, Udry JR. 2004. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 291:2229 -2236.
6. Stamm W. 2008. Chlamydia trachomatis infections of the adult, p 575- 593. In Holmes K, Sparling P, Stamm WE, Piot P, Wasserheit JW, Corey L, Cohen MS, Watts DH (ed), Sexually transmitted diseases. McGrawHill Book Co., New York, NY.
7. Darville T. 2005. Chlamydia trachomatis infections in neonates and young children. Semin. Pediatr. Infect. Dis. 16:235-244.
8. Arth C, Von Schmidt B, Grossman M, Schachter J. 1978. Chlamydial pneumonitis. J. Pediatr. 93:447- 449.
9. Stutman HR, Rettig PJ, Reyes S. 1984. Chlamydia trachomatis as a cause of pneumonitis and pleural effusion. J. Pediatr. 104:588 -591.
10. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. 1992. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex. Transm. Dis. 19:185-192.
11. Taylor HR. 2008. Trachoma: a blinding scourge from the Bronze Age to the twenty-first century, 1st ed. Haddington Press Pry Ltd., Victoria, Australia.
12. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. 2005. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J. Infect. Dis. 192:1836 -1844.
13. Gotz H, Lindback J, Ripa T, Arneborn M, Ramsted K, Ekdahl K. 2002. Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods? Scand. J. Infect. Dis. 34:28 -34.
14. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, Waiyaki P, Cheang M, Piot P, Ronald AR. 1991. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 163:233-239.
15. Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, Jellum E, Lehtinen M, Lenner P, Hakulinen T, Narvanen A, Pukkala E, Thoresen S, Youngman L, Paavonen J. 2001. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285:47-51.
16. Wang SP, Grayston JT. 1963. Classification of trachoma virus strains by protection of mice from toxic death. J. Immunol. 90:849-856.
17. Wang SP, Grayston J. 1984. Microimmunofluorescence serology of Chlamydia trachomatis. In Peterson EM, de la Maza LM (ed), Medical virology III. Elsevier Science Publishing, New York, NY.
18. Nigg C. 1942. An unidentified virus which produces pneumonia and systemic infection in mice. Science 95:49 -50.
19. Nigg C, Eaton MD. 1944. Isolation from normal mice of a pneumotropic virus which forms elementary bodies. J. Exp. Med. 79:497-510.
20. Grayston JT, Wang SP. 1978. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex. Transm. Dis. 5:73-77.
21. Dawson C, Wood TR, Rose L, Hanna L. 1967. Experimental inclusion conjunctivitis in man. 3. Keratitis and other complications. Arch. Ophthalmol. 78:341-349.
22. Nichols RL, Bell SD, Jr, Murray ES, Haddad NA, Bobb AA. 1966. Studies on trachoma. V. Clinical observations in a field trial of bivalent trachoma vaccine at three dosage levels in Saudi Arabia. Am. J. Trop. Med. Hyg. 15:639-647.
23. Woolridge RL, Grayston JT, Chang IH, Cheng KH, Yang CY, Neave C. 1967. Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children. Am. J. Ophthalmol. 63(Suppl):1645-1650.
24. Morrison RP, Belland RJ, Lyng K, Caldwell HD. 1989. Chlamydial disease pathogenesis. The 57-kDa chlamydial hypersensitivity antigen is a stress response protein. J. Exp. Med. 170:1271-1283.
25. Nichols RL, Bell SD, Jr, Haddad NA, Bobb AA. 1969. Studies on trachoma. VI. Microbiological observations in a field trial in Saudi Arabia of bivalent trachoma vaccine at three dosage levels. Am. J. Trop. Med. Hyg. 18:723-730.
26. Wang S, Grayston JT. 1962. Trachoma in the Taiwan monkey Macaca cyclopis. Ann. N. Y. Acad. Sci. 98:177-187.
27. Sun G, Pal S, Sarcon AK, Kim S, Sugawara E, Nikaido H, Cocco MJ, Peterson EM, de la Maza LM. 2007. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J. Bacteriol. 189:6222- 6235.
28. Nikaido H. 1992. Porins and specific channels of bacterial outer membranes. Mol. Microbiol. 6:435- 442.
29. Stephens RS, Sanchez-Pescador R, Wagar EA, Inouye C, Urdea MS. 1987. Diversity of Chlamydia trachomatis major outer membrane protein genes. J. Bacteriol. 169:3879 -3885.
30. Fitch WM, Peterson EM, de la Maza LM. 1993. Phylogenetic analysis of the outer-membrane-protein genes of Chlamydiae, and its implication for vaccine development. Mol. Biol. Evol. 10:892-913.
31. Grayston JT, Wang S. 1975. New knowledge of Chlamydiae and the diseases they cause. J. Infect. Dis. 132:87-105.
32. Caldwell HD, Kromhout J, Schachter J. 1981. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31:1161-1176.
33. Sun G, Pal S, Weiland J, Peterson EM, de la Maza LM. 2009. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 27:5020 -5025.
34. Schagger H, von Jagow G. 1987. Tricine-sodium dodecyl sulfatepolyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:368 -379.
35. Pal S, Fielder TJ, Peterson EM, de la Maza LM. 1994. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 62:3354 -3362.
36. Su H, Morrison RP, Watkins NG, Caldwell HD. 1990. Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis. J. Exp. Med. 172:203-212.
37. Pal S, Theodor I, Peterson EM, de la Maza LM. 2001. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69:6240-6247.
38. Pal S, Peterson EM, de la Maza LM. 2005. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73:8153- 8160.
39. Peterson EM, Zhong GM, Carlson E, de la Maza LM. 1988. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect. Immun. 56:885- 891.
40. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, Mitchell W, Olinger L, Tatusov RL, Zhao Q, Koonin EV, Davis RW. 1998. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282:754 -759.
41. Brunham RC, Zhang DJ, Yang X, McClarty GM. 2000. The potential for vaccine development against chlamydial infection and disease. J. Infect. Dis. 181(Suppl 3):S538 -S543.
42. de la Maza LM, Peterson EM. 2002. Vaccines for Chlamydia trachomatis infections. Curr. Opin. Investig. Drugs 3:980 -986.
43. Morrison RP, Caldwell HD. 2002. Immunity to murine chlamydial genital infection. Infect. Immun. 70:2741-2751.
44. Read TD, Brunham RC, Shen C, Gill SR, Heidelberg JF, White O, Hickey EK, Peterson J, Utterback T, Berry K, Bass S, Linher K, Weidman J, Khouri H, Craven B, Bowman C, Dodson R, Gwinn M, Nelson W, DeBoy R, Kolonay J, McClarty G, Salzberg SL, Eisen J, Fraser CM. 2000. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res. 28:1397-1406.
45. Fielder TJ, Pal S, Peterson EM, de la Maza LM. 1991. Sequence of the gene encoding the major outer membrane protein of the mouse pneumonitis biovar of Chlamydia trachomatis. Gene 106:137-138.
46. de la Maza LM, Pal S, Khamesipour A, Peterson EM. 1994. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect. Immun. 62:2094 -2097.
47. Pal S, Peterson EM, de la Maza LM. 1999. A murine model for the study of Chlamydia trachomatis genital infections during pregnancy. Infect. Immun. 67:2607-2610.
48. Pal S, Peterson EM, de la Maza LM. 2004. New murine model for the study of Chlamydia trachomatis genitourinary tract infections in males. Infect. Immun. 72:4210-4216.
49. Digiacomo RF, Gale JL, Wang SP, Kiviat MD. 1975. Chlamydial infection of the male baboon urethra. Br. J. Vener. Dis. 51:310 -313.
50. Ramsey KH, DeWolfe JL, Salyer RD. 2000. Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis. Infect. Immun. 68:7186 -7189.
51. Ramsey KH, Cotter TW, Salyer RD, Miranpuri GS, Yanez MA, Poulsen CE, DeWolfe JL, Byrne GI. 1999. Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection. Infect. Immun. 67:3019 -3025.
52. Brunham RC, Rey-Ladino J. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5:149 -161.
53. Tuffrey M, Alexander F, Conlan W, Woods C, Ward M. 1992. Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein. J. Gen. Microbiol. 138(Part 8):1707-1715.
54. Li W, Guentzel MN, Seshu J, Zhong G, Murthy AK, Arulanandam BP. 2007. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin. Vaccine Immunol. 14:1537-1544.
55. Morrison SG, Morrison RP. 2001. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4 and CD8 T cells. Infect. Immun. 69:2643-2649.
56. Morrison SG, Morrison RP. 2005. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175:7536 -7542.
57. Ortiz L, Demick KP, Petersen JW, Polka M, Rudersdorf RA, Van der Pol B, Jones R, Angevine M, DeMars R. 1996. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J. Immunol. 157:4554-4567.
58. Hanada K, Yewdell JW, Yang JC. 2004. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427:252-256.
59. Musson JA, Morton M, Walker N, Harper HM, McNeill HV, Williamson ED, Robinson JH. 2006. Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes. J. Biol. Chem. 281: 26129-26135.
60. Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling SK, Bernhardt G, Park JH, Yang JC, Sun PD, Singer A. 2012. Alpha beta T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibodylike recognition specificities. Immunity 36:79 -91.
61. Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der Bruggen P, Boon T, Van den Eynde BJ. 2004. An antigenic peptide produced by peptide splicing in the proteasome. Science 304:587- 590.
62. Warren EH, Vigneron NJ, Gavin MA, Coulie PG, Stroobant V, Dalet A, Tykodi SS, Xuereb SM, Mito JK, Riddell SR, Van den Eynde BJ. 2006. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313:1444 -1447.
63. Tifrea DF, Sun G, Pal S, Zardeneta G, Cocco MJ, Popot JL, de la Maza LM. 2011. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine. Vaccine 29:4623- 4631.
64. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM. 2002. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect. Immun. 70:6021- 6031.
65. Liu L, Hao Y, Luo Z, Huang Y, Hu X, Liu Y, Shao Y. 2012. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization. Vaccine 30:4135- 4143.
66. Kachko A, Kochneva G, Sivolobova G, Grazhdantseva A, Lupan T, Zubkova I, Wells F, Merchlinsky M, Williams O, Watanabe H, Ivanova A, Shvalov A, Loktev V, Netesov S, Major ME. 2011. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles. Vaccine 30:69 -77.
67. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN. 2012. Preexisting influenzaspecific CD4 T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18:274 -280.
68. de la Maza MA, de la Maza LM. 1995. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 13:119 -127.
69. Bryan JT. 2007. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 25:3001-3006.
70. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765.